SOL-1 Phase 3 Data Presentation at OSN New York & Retina
Investor Day 2026
Watch Investor Day by Chapter
1.) Intro & Overview (Pravin U. Dugel, MD)
2.) SOL-1 Data & Clinical Program Review (Nadia K. Waheed, MD, MPH)
3.) U.S. Regulatory Strategy in Wet AMD (Peter K. Kaiser, MD)
4.) NDA Submission Strategy (Peter K. Kaiser, MD & Arthur Ciociola, PhD)
5.) Preparing for a Successful Launch (David Robinson)
6.) SOL-R- Defining Non-Inferiority Success (Jeffrey S. Heier, MD)
7.) KOL Perspectives (Featuring Arshad Khanani, MD; Lejla Vajzovic, MD; Darius Moshfeghi, MD)
8.) Summary & Takeaways (Pravin U. Dugel, MD)
9.) Audience Q&A (All)
All investigational product candidates are currently undergoing clinical evaluation. This content is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval or other regulatory authority approval.
Upcoming Events
November 17, 2026 at 12:00 PM GMT
Recent Events anchor do not remove